Nature Communications (Aug 2017)
Absence of Grail promotes CD8+ T cell anti-tumour activity
- Cara Haymaker,
- Yi Yang,
- Junmei Wang,
- Qiang Zou,
- Anupama Sahoo,
- Andrei Alekseev,
- Divyendu Singh,
- Krit Ritthipichai,
- Yared Hailemichael,
- Oanh N. Hoang,
- Hong Qin,
- Kimberly S. Schluns,
- Tiejun Wang,
- Willem W. Overwijk,
- Shao-Cong Sun,
- Chantale Bernatchez,
- Larry W. Kwak,
- Sattva S. Neelapu,
- Roza Nurieva
Affiliations
- Cara Haymaker
- Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center
- Yi Yang
- Department of Immunology, M.D. Anderson Cancer Center
- Junmei Wang
- Department of Immunology, M.D. Anderson Cancer Center
- Qiang Zou
- Department of Immunology, M.D. Anderson Cancer Center
- Anupama Sahoo
- Department of Immunology, M.D. Anderson Cancer Center
- Andrei Alekseev
- Department of Immunology, M.D. Anderson Cancer Center
- Divyendu Singh
- Department of Immunology, M.D. Anderson Cancer Center
- Krit Ritthipichai
- Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center
- Yared Hailemichael
- Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center
- Oanh N. Hoang
- Department of Immunology, M.D. Anderson Cancer Center
- Hong Qin
- Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center
- Kimberly S. Schluns
- Department of Immunology, M.D. Anderson Cancer Center
- Tiejun Wang
- Department of Radiation Oncology, The Second Hospital of Jilin University
- Willem W. Overwijk
- Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center
- Shao-Cong Sun
- Department of Immunology, M.D. Anderson Cancer Center
- Chantale Bernatchez
- Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center
- Larry W. Kwak
- Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center
- Sattva S. Neelapu
- Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center
- Roza Nurieva
- Department of Immunology, M.D. Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-017-00252-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Grail is an E3 ubiquitin ligase that inhibits T-cell receptor signalling in CD4+ T cells. Here the authors show Grail also limits IL-21 receptor expression and function in CD8+ T cells, is overactive in these cells in patients with lymphoma, and promotes tumour development in a lymphoma transplant mouse model.
